For the Inventor, By the Inventor

Enter assignee name

National Center of Neurology and Psychiatry

USPTO Granted Patents = 40

CIPO Patents = 1

EPO Patents = 20

Forward Citations = 381

Loading Chart...

Loading Chart...

57 inventors (with patents filed for the assignee):

Shin'ichi Takeda (27 out of 27 patents)

Tetsuya Nagata (19 out of 108 patents)

Naoki Watanabe (17 out of 19 patents)

4. Youhei Satou (13 out of 13 patents)

5. Haruna Seo (5 out of 5 patents)

6. Yoshitsugu Aoki (5 out of 5 patents)

7. Takashi Yamamura (5 out of 8 patents)

8. Yukiko Enya (4 out of 4 patents)

9. Takashi Okada (3 out of 54 patents)

10. Hiromi Kinoh (3 out of 3 patents)

11. Yuuichirou Tone (3 out of 3 patents)

12. Hiroshi Kunugi (3 out of 3 patents)

13. Yuichiro Tone (3 out of 3 patents)

14. Tatsushi Wakayama (2 out of 2 patents)

15. Masakazu Nakamura (2 out of 30 patents)

Core Competencies:

GM-CSF-Producing T-Cell Control

Th1/Th2 Immune Balance

Antisense Nucleic Acids

IL-6 Inhibitor

Mental Disease Biomarkers

Drug Delivery Particles

Muscle Differentiation Inducers

Cognitive Function Testing

Mood Disorder Detection

Multiple Sclerosis Prognosis

Progressive Immune Demyelinating Diseases

Adeno-Associated Virus Mutants

40 patents: Sort by Forward Citations

1. 12447167 - GM-CSF-producing t-cell control agent and Th1/Th2 immune balance regulator (2025-10-21),

2. 12157772 - Prophylactic agent, onset-suppressing agent or therapeutic agent for progressive immune demyelinating diseases (2024-12-03),

3. 12060556 - Antisense nucleic acids (2024-08-13),

4. 11981894 - Antisense nucleic acids (2024-05-14),

5. 11851486 - Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils (2023-12-26),

6. 11781140 - Antisense nucleic acid inducing skipping of exon 51 (2023-10-10),

7. 11655493 - Biomarker for mental disease (2023-05-23),

8. 11655472 - Antisense nucleic acid that induces skipping of exon 50 (2023-05-23),

9. 11555221 - Method for detecting mood disorders (2023-01-17),

10. 11193125 - Antisense nucleic acids (2021-12-07),

11. 11191733 - Drug delivery particle and method for producing the same (2021-12-07),

12. 11174317 - Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient (2021-11-16),

13. 11062175 - System, method, and program for estimating reduced attention state, and storage medium storing the same program (2021-07-13),

14. 11053497 - Antisense nucleic acids (2021-07-06),

15. 11028131 - Mutant of adeno-associated virus (AAV) capsid protein (2021-06-08),

The National Center of Neurology and Psychiatry (NCNP) is a leading medical research institution in Japan. It focuses on the study and treatment of neurological and psychiatric disorders. With state-of-the-art facilities and a team of dedicated researchers and clinicians, NCNP aims to advance knowledge in these fields and provide better care for patients. Their website provides in-depth information on their research activities, clinical services, and educational programs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

40 Patents

#1 in Kodaira

#1,932 in Japan

#16,565 in the World

National Center of Neurology and Psychiatry

Forward Citations = 381

57 inventors:

Shin'ichi Takeda (27 out of 27 patents)

Tetsuya Nagata (19 out of 108 patents)

Naoki Watanabe (17 out of 19 patents)

4. Youhei Satou (13 out of 13 patents)

5. Haruna Seo (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…